Drug intelligence / Profile preview

CALCIVID

Development stage: Unknown
Lead developer: Sanifortpharma
Modality: Small Molecules
Administration: Oral

Overview

CALCIVID is an oral dietary supplement developed by Sanifortpharma, formulated with a combination of calcium carbonate and vitamin D3 (cholecalciferol) to support skeletal health. It is primarily indicated for the prevention and treatment of calcium and vitamin D deficiencies, contributing to the maintenance of strong bones and teeth. Vitamin D3 enhances the intestinal absorption of calcium and regulates bone mineralization by acting as an agonist at the Vitamin D receptor, while calcium serves as a fundamental structural component of the bone matrix. The product is marketed in various European countries in forms such as chewable tablets and sachets.

Brand names: CALCIVID
Other names: calcium carbonate + cholecalciferolcalcium carbonate + vitamin D3

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on CALCIVID.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CALCIVID.

Explore the full profile